- Home
- CYCN vs POAI Comparison
CYCN vs POAI Comparison
Compare CYCN & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- POAI
- Stock Information
- Founded
- CYCN 2018
- POAI 2002
- Country
- CYCN United States
- POAI United States
- Employees
- CYCN N/A
- POAI N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- CYCN Health Care
- POAI Health Care
- Exchange
- CYCN Nasdaq
- POAI Nasdaq
- Market Cap
- CYCN 8.4M
- POAI 8.5M
- IPO Year
- CYCN N/A
- POAI N/A
- Fundamental
- Price
- CYCN $4.19
- POAI $1.48
- Analyst Decision
- CYCN
- POAI Hold
- Analyst Count
- CYCN 0
- POAI 1
- Target Price
- CYCN N/A
- POAI N/A
- AVG Volume (30 Days)
- CYCN 5.7M
- POAI 5.9M
- Earning Date
- CYCN 03-04-2025
- POAI 03-27-2025
- Dividend Yield
- CYCN N/A
- POAI N/A
- EPS Growth
- CYCN N/A
- POAI N/A
- EPS
- CYCN N/A
- POAI N/A
- Revenue
- CYCN $194,000.00
- POAI $1,484,223.00
- Revenue This Year
- CYCN N/A
- POAI N/A
- Revenue Next Year
- CYCN N/A
- POAI $569.48
- P/E Ratio
- CYCN N/A
- POAI N/A
- Revenue Growth
- CYCN N/A
- POAI N/A
- 52 Week Low
- CYCN $1.27
- POAI $0.55
- 52 Week High
- CYCN $9.47
- POAI $3.76
- Technical
- Relative Strength Index (RSI)
- CYCN 59.43
- POAI 55.07
- Support Level
- CYCN $2.81
- POAI $1.33
- Resistance Level
- CYCN $6.25
- POAI $1.64
- Average True Range (ATR)
- CYCN 0.57
- POAI 0.23
- MACD
- CYCN 0.19
- POAI -0.01
- Stochastic Oscillator
- CYCN 47.85
- POAI 19.01
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.